抗苗勒管激素截断值判定多囊卵巢形态的前瞻性验证:HARMONIA研究
在芬兰北部出生队列1986的948名育龄女性中前瞻性验证抗苗勒管激素(AMH)截断值3.2 ng/mL判定多囊卵巢形态(PCOM)的效能。128例PCOM阳性者AMH中位数6.21 ng/mL高于820例对照的2.16 ng/mL,总体符合率79.9%,受试者工作特征曲线下面积94.0%。作者认为该截断值获成功验证,支持将AMH检测作为替代经阴道超声的便捷诊断工具。
要点
- AMH截断值3.2 ng/mL判定PCOM与经阴道超声的总体符合率为79.9%。
- PCOM阳性者AMH中位数6.21 ng/mL,对照者2.16 ng/mL。
- 受试者工作特征曲线下面积为94.0%(95%CI 91.9%-96.2%)。
核心结论
- Elecsys AMH Plus免疫分析法截断值3.2 ng/mL获成功验证,检测PCOM准确性高。
- 基于现行指南对PCOM检测作为PCOS诊断一部分的建议,数据支持将AMH检测作为相比经阴道超声更易获取的诊断检查工具。
研究设计与样本
- 前瞻性、基于人群的非干预性研究。
- 研究对象为芬兰北部出生队列1986的女性及在芬兰北部地区出生的、与芬兰北部出生队列1986出生时间相差1.5年内的女性。
- 主要分析人群948例,包括128例PCOM阳性病例和820例PCOM阴性对照,平均年龄35.2岁。
- 采用Roche Elecsys AMH Plus免疫分析法测定血清AMH,以经阴道超声判定PCOM状态评估截断值3.2 ng/mL的效能。
主要发现
- 病例组AMH中位数为6.21 ng/mL,对照组为2.16 ng/mL。
- 表型A的AMH中位数最高,为9.05 ng/mL;表型C和D相似,分别为5.67 ng/mL和5.83 ng/mL。
- 应用3.2 ng/mL截断值,128例病例中118例、820例对照中639例与经阴道超声结果一致,总体符合率79.9%。
- 在各PCOM阳性PCOS表型及不同体重指数类别中均观察到AMH与PCOM状态的一致性。
- 预测病例对照状态的受试者工作特征曲线下面积为94.0%(95%CI 91.9%-96.2%)。
关键数值与推荐
- AMH截断值为3.2 ng/mL。
- 总体符合率为79.9%。
- 受试者工作特征曲线下面积为94.0%(95%CI 91.9%-96.2%)。
临床怎么用
- 基于现行指南对PCOM检测作为PCOS诊断一部分的建议,数据支持将AMH检测作为相比经阴道超声更易获取的诊断检查工具。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To verify the anti-Müllerian hormone (AMH) cutoff (3.2 ng/mL) for the determination of polycystic ovarian morphology (PCOM) as part of the latest polycystic ovary syndrome (PCOS) diagnosis in an independent prospective cohort of women of reproductive age. DESIGN: A prospective, population-based, noninterventional study. SUBJECTS: Women enrolled in the Northern Finland Birth Cohort 1986 and women born in the Northern Finland region within 1.5 years of the Northern Finland Birth Cohort 1986. EXPOSURE: Antimüllerian hormone was measured in serum samples using the Roche Elecsys AMH Plus immunoassay (Roche Diagnostics International Ltd, Rotkreuz, Switzerland). Assessment of the performance of the AMH cutoff of 3.2 ng/mL to identify PCOM status determined by transvaginal ultrasound (TVUS). MAIN OUTCOME MEASURES: The number of PCOM-positive cases (participants with PCOS phenotypes A, C, or D) and negative controls according to serum AMH or TVUS. Other measures included PCOM status within selected PCOS phenotypes and demographic/clinical factors including body mass index. RESULTS: The primary analysis population (N = 948) comprised 128 PCOM-positive cases and 820 negative controls (PCOM-negative), with a mean age of 35.2 years. The median AMH levels were numerically higher in cases (6.21 ng/mL) than in controls (2.16 ng/mL), with highest levels observed for phenotype A (9.05 ng/mL) and similar levels observed for phenotypes C and D (5.67 ng/mL and 5.83 ng/mL, respectively). Applying the AMH cutoff of 3.2 ng/mL, 118 of 128 cases and 639 of 820 controls were identified in accordance with TVUS (overall percent agreement, 79.9%). Agreement of AMH with PCOM status was also observed across all PCOM-positive PCOS phenotypes and body mass index categories. The area under the receiver operating characteristic curve for prediction of case-control status was 94.0% (95% confidence interval, 91.9%-96.2%). CONCLUSION: The Elecsys AMH Plus immunoassay cutoff of 3.2 ng/mL was successfully verified, showing high accuracy to detect PCOM. On the basis of current guideline recommendations for the detection of PCOM as part of PCOS diagnosis, these data support use of the AMH test as an easy-access diagnostic workup tool compared with TVUS. TRIAL REGISTRATION NUMBER: NCT05527353.
引用
- Piltonen TT, Kinnunen J, Komsi E, et al. Prospective validation of anti-Müllerian hormone cutoff to determine polycystic ovarian morphology: HARMONIA study. Fertil Steril. 2025. PMID: 40398715. doi:10.1016/j.fertnstert.2025.05.147
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。